ABSTRACT
Monoclonal antibodies are very special molecules and are so designed that these easily bind to particular antigens. Their emergence acts as pioneering tools in therapeutic biologics. This can offer specific and targeted treatments for a big collection of diseases. This includes various types of cancers, autoimmune disorders, and infectious diseases. mAbs development comprises sophisticated techniques like hybridoma technology, phage display, and single B-cell antibody technology. This has resulted in advanced specificity and efficacy of these therapeutic agents. Their humanization and affinity maturation have further reduced adverse effects, and so their use becomes a preferred choice in clinical applications. So far, over 117 mAbs and their derivatives have been approved for clinical use, while their role in personalized medicine is further growing day by day. No doubt, all this will provide patients with novel and life-changing treatment options. The expanding therapeutic applications of monoclonal antibodies mark their transformative potential in modern medicine. Their ability for targeted and personalized approaches has brought a paradigm shift in the approach to disease management. Research and development are a continuous process, and so, as a result, we can expect more promising, greater achievements and more profound impacts on patient care after further refining of these mAbs.
